Keywords
Abstract
Arterial gipertenziya ko‘p omilli kasallik bo‘lib, uning yuzaga kelishi irsiy moyillik, turmush tarzi, buyrak faoliyati va qon tomirlarni boshqaruvchi tizimlarning o‘zaro ta’siriga bog‘liq. Oksidlanish jarayonlariga daxldor genetik belgilarni o‘rganish kasallik mexanizmlarini tushunishga yordam berishi mumkin, lekin birgina polimorfizm asosida klinik tashxis qo‘yish mumkin emas. Zamonaviy yo‘riqnomalar xavfni baholashda qon bosimini to‘g‘ri o‘lchash va umumiy yurak-qon tomir xavfiga ustuvor ahamiyat beradi [1], [2]. Ushbu maqolada SOD2 geni Ala16Val polimorfizmining guruhlar bo‘yicha taqsimoti ehtiyotkor statistik talqin doirasida ko‘rib chiqildi.
Ochiq e’lon qilingan jamlangan ma’lumotlarda arterial gipertenziyali 96 bemor va 95 nafar taqqoslash ishtirokchisi kiritilgan. Ala/Val genotipi bemorlarning 57 nafarida (59,4%), taqqoslash guruhining 40 nafarida (42,1%) qayd etilgan. Mazkur solishtirishda imkoniyatlar nisbati 2,0 va p qiymati 0,02 deb berilgan. Ala/Ala genotipi mos ravishda 21,9% va 34,7% holatda kuzatilgan. Boshqa genotiplar bo‘yicha farqlar bir xil darajada ishonchli bo‘lmaganligi sababli barcha genetik ko‘rsatkichlarni bir xil xulosaga birlashtirish mumkin emas.
Ushbu kuzatuv genetik assotsiatsiyani individual bemor uchun tayyor bashoratga aylantirishdagi cheklovlarni ko‘rsatadi. Namuna hajmi, populyatsiya tarkibi, chalkashtiruvchi omillar va mustaqil takroriy tasdiq natijani talqin qilishda muhimdir [3], [4]. Kundalik yordamda esa gipertenziyani tashxislash, uy sharoitida qon bosimini kuzatish, tuz iste’moli va jismoniy faollikni boshqarish birlamchi vazifa bo‘lib qoladi. Maqola yig‘ma genotip ko‘rsatkichlarining ikkilamchi tahlili bo‘lib, yangi molekulyar tekshiruv o‘tkazilganini yoki marker klinik qo‘llashga tayyorligini bildirmaydi.
Polimorfizm bilan bog‘liq natijalar sog‘lom odamlar uchun genetik tekshiruvni ommaviy tavsiya etish darajasidagi dalil emas. Agar biomarker kelajakda qo‘llanilsa, u mavjud xavf bahosiga qanday qo‘shimcha axborot berishi va bemor uchun qaysi qarorni o‘zgartirishi ko‘rsatilishi kerak. Genetik maslahatda tasodifiy assotsiatsiya bilan muqarrar tashxis farqlanadi. Bemorni qo‘rqitmaydigan, ilmiy chegaralari ochiq bayon etilgan tushuntirish klinik etikaning zarur tarkibiy qismidir.
References
1. European Society of Cardiology. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912–4018. https://doi.org/10.1093/eurheartj/ehae178
2. European Society of Hypertension. 2023 ESH Guidelines for the management of arterial hypertension. https://www.eshonline.org/guidelines/2023-guidelines/
3. WHO. Hypertension. Fact sheet, 2025. https://www.who.int/news-room/fact-sheets/detail/hypertension
4. WHO. Global report on hypertension: the race against a silent killer. 2023. https://www.who.int/publications/i/item/9789240081062
5. International Society of Hypertension. 2020 Global Hypertension Practice Guidelines. J Hypertens. 2020. https://doi.org/10.1097/HJH.0000000000002453
6. Whelton P.K. et al. 2017 ACC/AHA Guideline for High Blood Pressure in Adults. Hypertension. 2018. https://doi.org/10.1161/HYP.0000000000000065
7. European Society of Cardiology. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018. https://doi.org/10.1093/eurheartj/ehy339
8. KDIGO. Clinical Practice Guideline for the Management of Blood Pressure in CKD. 2021. https://kdigo.org/guidelines/blood-pressure-in-ckd/
9. KDIGO. Clinical Practice Guideline for the Evaluation and Management of CKD. 2024. https://kdigo.org/guidelines/ckd-evaluation-and-management/
10. WHO. HEARTS: technical package for cardiovascular disease management in primary health care. https://www.who.int/teams/noncommunicable-diseases/hypertension-control/hearts